• International Society of Paediatric Oncology Europe Neuroblastoma

High-Risk Neuroblastoma Study

Patients with neuroblastoma that has amplification of the MYCN gene (a genetic marker of more aggressive disease), or those aged more than 1 year with metastatic disease (neuroblastoma that has spread to other parts of the body) will generally be treated according to the SIOPEN high-risk study.

Neuroblastoma in high-risk patients is often difficult to treat and requires a combination of intensive chemotherapy, surgery and radiotherapy. The current treatment schedule for high-risk disease also includes myeloablative chemotherapy (also known as ‘high-dose’ therapy) with stem cell rescue, immunotherapy with anti-GD2 antibody and differentiation therapy with 13-cis retinoic acid.

Some of the questions posed in the current high-risk study have already been answered, leading to the routine use of G-CSF during induction chemotherapy and one particular type of chemotherapy used for high-dose/myeloablative treatment.

The current high-risk study is seeking to answer two further questions:

  • 1) Which schedule of chemotherapy gives the best results in induction (the first chemotherapy treatment given)? The study will compare the current standard European protocol of ‘Rapid COJEC’ with an alternative regimen previously used in North America (known as ‘modified N7’).
  • 2) During immunotherapy, does the addition of IL2 to anti-GD2 antibody treatment improve outcomes without unacceptable side effects? This part of the trial has reached adequate patient numbers and the results are being analysed.

SIOPEN meetings

Forthcoming meetings:

Berlin (Germany) AGM

25-27 October 2017 

click for more information


SIOPEN Verein zur Foderung der Neuroblastomforschung is an Association registered in Austria and recognised as a non-profit organisation according to the Austrian Federal Tax Code (Bundesabgabenordnung BAO). Registration number ZVR 396592912. The SIOPEN Association was officially established on 20 January 2009.

This website makes use of stock photography and images do not represent particular individuals treated by SIOPEN institutions.